Table 1.
Patient characteristics
| Characteristics | Hypocellular MDS (n=253) | Hyper/normocellular MDS (n=1725) | p-value |
|---|---|---|---|
| Median age, years (range) | 65 (13–94) | 67 (16–89) | 0.216 |
| Male sex, n (%) | 163 (64) | 1172 (67.9) | 0.267 |
| Hemoglobin, g/dl | 9.6 (5.5–14.5) | 9.7 (3.7–16.4) | 0.786 |
| Platelet, ×109/l | 61 (2–457) | 72 (1–1195) | 0.019 |
| WBC, ×109/l | 2.5 (0.2–35.1) | 4.1 (0.3–99) | < 0.001 |
| ANC, ×109/l | 0.95 (0–14.20) | 2.01 (0–74.69) | < 0.001 |
| BM cellularity, % | 15 (1–20) | 70 (25–100) | < 0.001 |
| BM blast, % | 7 (0–19) | 5 (0–19) | 0.098 |
| LDH, IU/l | 558 (182–3434) | 571 (72–10000) | 0.155 |
| β-2 microglobulin, mg/l | 2.4 (0.1–20) (n=187) | 3.1 (0.1–20) (n=1291) | < 0.001 |
| Therapy-related, n (%) | 62 (25) | 377 (21.9) | 0.219 |
| Transfusion, n (%) | 131 (52) | 486 (28) | < 0.001 |
| Performance status 0–1, n (%) | 228 (90) | 1518 (88) | 0.327 |
| IPSS score, n (%) | < 0.001 | ||
| Low | 27 (11) | 297 (18) | |
| Int-1 | 82 (32) | 682 (40) | |
| Int-2 | 110 (43) | 515 (31) | |
| High | 34 (13) | 231 (11) | |
| FAB classification, n (%) | n=253 | n= 1725 | < 0.001 |
| RA | 75 (30) | 376 (22) | |
| RARS | 20 (8) | 185 (11) | |
| RAEB | 125 (49) | 636 (37) | |
| RAEB-T | 28 (11) | 168 (10) | |
| CMML | 5 (2) | 360 (21) | |
| IPSS cytogenetics, n (%) | 0.086 | ||
| Good | 135 (53) | 965 (57) | |
| Intermediate | 32 (13) | 475 (28) | |
| Poor | 86 (34) | 263 (15) | |
| AML transformation by IPSS | 29 (11) | 224 (13) | |
| Low (n=25) | 2 (8) | 17 (6) | |
| Int-1 (n=84) | 5 (6) | 72 (11) | |
| Int-2 (n=111) | 19 (17) | 87 (17) | |
| High (n=13) | 4 (31) | 39 (22) | |
| Median time to AML, weeks | 26 (1–329) | 27 (1–460) | 0.497 |
| Median survival, weeks | |||
| Overall | 71 | 64 | 0.312 |
| De novo | 94 | 78 | 0.040 |
| Therapy-related | 35 | 46 | 0.069 |